# Plain Language Summary: Ensuring Timely Access to Generics Act of 2021

This bill is designed to speed up the process of getting generic medications to patients and pharmacies. Generic drugs are cheaper versions of brand-name medications that work the same way but cost significantly less. Right now, there can be long delays between when a brand-name drug's patent expires and when generic versions actually become available for patients to buy. This bill aims to eliminate those unnecessary delays so people can access affordable medications faster.

The main problem the bill addresses is that pharmaceutical companies sometimes use legal tactics to keep generic competitors off the market even after their patent protection ends. They might file lawsuits, make small changes to their drugs to extend patents, or use other strategies that can delay generic versions by months or even years. During these delays, patients have no choice but to keep paying high prices for brand-name drugs. This bill would tighten the rules around these delay tactics and make it harder for companies to use them, ensuring that once a patent legitimately expires, generic versions can reach pharmacies and patients quickly.

The practical impact for everyday people is straightforward: you'd likely pay less for medications sooner. If you take prescription drugs regularly, this could mean significant savings on your pharmacy bills. For people without insurance or with high deductibles, the difference between paying $200 a month for a brand-name drug and $20 for a generic version could be life-changing. The bill essentially tries to make sure that the competitive market for generic drugs works the way it's supposed to, bringing prices down as quickly as possible once patents expire.

Ensuring Timely Access to Generics Act of 2021

Shaheen, Jeanne

Ensuring Timely Access to Generics Act of 2021 This bill imposes requirements related to third-party petitions concerning an application for Food and Drug Administration (FDA) approval to market a generic drug or biosimilar. (The current statute refers to these petitions as citizen petitions, which typically involve requests that the FDA take certain actions, such as requiring additional warnings on a drug.) Under the bill, the FDA may deny a citizen petition that (1) was submitted primarily to delay the approval of the relevant application, or (2) does not on its face raise valid scientific or regulatory issues. Currently, the FDA may deny a petition as an attempt at delay only if the petition meets both of these requirements. The bill also requires the FDA to establish procedures for referring such a delaying petition to the Federal Trade Commission. The bill also expressly requires a third party, before filing a lawsuit to force the FDA to set aside or prevent market approval of a generic drug or biosimilar, to first file a citizen petition with the information and arguments that form the basis of the lawsuit. A citizen petition must be filed within 60 days of when the filer knew or reasonably should have known the information that forms the basis of the petition.